Brought to you by 
New Zealand firm Proacta gets $8.2mm in Series A; adds $4mm
26 Jan 2006
Executive Summary
Cancer company Proacta Therapeutics Ltd. (a cooperative venture between the University of Auckland and Stanford University) brought in $8.2mm (NZD12.5mm) with a Series A venture round led by GBS Venture Partners. Also participating in the financing were Endeavour i-cap, Genentech, New Zealand Venture Investment Fund, No. 8 Ventures Management Ltd., and Roche's venture capital arm Roche Venture Fund.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
New Zealand firm Proacta gets $8.2mm in Series A; adds $4mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice